NEWS

Coherus BioSciences to Divest its Ophthalmology Franchise to Sandoz for $170M Up Front

Shots : Coherus signs an agreement with Sandoz to divest its ophthalmology franchise which includes a lead asset Cimerli (ranibizumab-eqrn) along with its supporting commercial infrastructure As per the terms of the agreement, Coherus will receive an all-cash consideration of $170M as up-front payment along with an additional amount for Cimerli product inventory &…

January 4, 2024

Glenmark Introduces Lirafit (Biosimilar, Liraglutide) for Type 2 Diabetes Mellitus in India

Shots : Following the approval from the Drug Controller General of India (DCGI), Glenmark has introduced the first biosimilar of Liraglutide under the brand name Lirafit (1.2mg, per day) for managing type 2 diabetes mellitus in India Lirafit gained approval based on a 24wks. study in type 2 diabetes mellitus Indian adult patients which showed…

January 3, 2024

Alvotech Reports Topline Results from the Study of AVT06 (Biosimilar, Eylea) for Eye Disorders

Shots : The (AVT06-GL-C01) confirmatory trial investigated the efficacy, safety, and immunogenicity of AVT06 vs Eylea for the treatment of neovascular (wet) AMD  The results revealed that the trial met its 1EP of baseline to wk. 8 in Best-Corrected Visual Acuity (BCVA) showing therapeutic similarity between AVT06 and Eylea AVT06, recombinant fusion protein, binds…

January 3, 2024

BMS Reports EMA’s Validation of Augtyro (repotrectinib) for the Treatment of Solid Tumors

Shots: The EMA has validated MAA of Augtyro for treating adults and pediatric patients (12yrs. & older) with ROS1+ and NTRK+ locally advanced or metastatic solid tumors incl. NSCLC The application was based on two P-I/II (TRIDENT-1 & CARE) trials assessing the safety, tolerability, PK and anti-tumor activity in adults with ROS1+ NSCLC or NTRK+…

January 2, 2024

LEO Pharma’s Anzupgo (Delgocitinib) Gains the CHMP’s Positive Opinion to Treat Moderate to Severe Chronic Hand Eczema (CHE)

Shots: The CHMP has granted positive opinion to Anzupgo cream (topical pan-JAK inhibitor) for treating moderate to severe chronic hand eczema (CHE), inadequately managed by topical corticosteroids Opinion was based on P-III (DELTA 1 & DELTA 2) trials assessing the safety & efficacy of Anzupgo (BID) vs vehicle for moderate to severe CHE. Those…

July 26, 2022